Dermira Inc (NASDAQ:DERM) saw some unusual options trading on Thursday. Stock traders purchased 4,688 call options on the company. This represents an increase of approximately 5,760% compared to the average daily volume of 80 call options.
A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Dermira from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a report on Wednesday. BidaskClub upgraded Dermira from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright assumed coverage on Dermira in a report on Thursday, February 14th. They issued a “buy” rating and a $13.00 target price for the company. Finally, Raymond James upgraded Dermira from an “underperform” rating to a “market perform” rating and set a $6.71 target price for the company in a report on Thursday, January 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Dermira has a consensus rating of “Buy” and an average target price of $14.90.
Shares of DERM opened at $7.07 on Friday. The stock has a market cap of $314.22 million, a price-to-earnings ratio of -1.61 and a beta of 1.24. The company has a debt-to-equity ratio of 5.21, a current ratio of 5.29 and a quick ratio of 5.25. Dermira has a 12 month low of $6.00 and a 12 month high of $27.83.
ILLEGAL ACTIVITY WARNING: “Dermira Sees Unusually Large Options Volume (DERM)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2019/02/22/dermira-sees-unusually-large-options-volume-derm.html.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Further Reading: Consumer Price Index (CPI)
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.